Literature DB >> 3125114

Selective pressure of antistaphylococcal chemotherapeutics in favour of Pseudomonas aeruginosa in cystic fibrosis.

A Bauernfeind1, G Emminger, G Hörl, B Lorbeer, B Przyklenk, C Weisslein-Pfister.   

Abstract

Pseudomonas aeruginosa is insensitive against the majority of oral chemotherapeutics active against staphylococci. During application of such compounds in patients colonized by P. aeruginosa the concentration of P. aeruginosa increased in the majority of treatment episodes by factors between 2.5 and 50000. So, from a microbiological point of view the application of purely antistaphylococcal drugs should not be used prophylactically against staphylococci.

Entities:  

Mesh：

Year:  1987        PMID： 3125114     DOI： 10.1007/bf01647240

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


  5 in total

1.  A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis.

Authors:  V A Loening-Baucke; E Mischler; M G Myers
Journal:  J Pediatr       Date:  1979-10       Impact factor: 4.406

2.  Qualitative and quantitative microbiological analysis of sputa of 102 patients with cystic fibrosis.

Authors:  A Bauernfeind; R M Bertele; K Harms; G Hörl; R Jungwirth; C Petermüller; B Przyklenk; C Weisslein-Pfister
Journal:  Infection       Date:  1987 Jul-Aug       Impact factor: 3.553

3.  Selective media for the quantitation of bacteria in cystic fibrosis sputum.

Authors:  K Wong; M C Roberts; L Owens; M Fife; A L Smith
Journal:  J Med Microbiol       Date:  1984-04       Impact factor: 2.472

4.  Bacteriological effects of anti-Pseudomonas aeruginosa chemotherapy in cystic fibrosis.

Authors:  A Bauernfeind; G Emminger; G Hörl; S Ott; B Przyklenk; C Weisslein-Pfister
Journal:  Infection       Date:  1987       Impact factor: 3.553

5.  Bacteriology of sputum in cystic fibrosis: evaluation of dithiothreitol as a mucolytic agent.

Authors:  M R Hammerschlag; L Harding; A Macone; A L Smith; D A Goldmann
Journal:  J Clin Microbiol       Date:  1980-06       Impact factor: 5.948
  5 in total
  4 in total

Review 1.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

2.  Treatment of infections in patients with cystic fibrosis.

Authors:  M I Marks
Journal:  Infection       Date:  1987       Impact factor: 3.553

Review 3.  Microbiology of airway disease in patients with cystic fibrosis.

Authors:  P H Gilligan
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

Review 4.  Lung infections associated with cystic fibrosis.

Authors:  Jeffrey B Lyczak; Carolyn L Cannon; Gerald B Pier
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.